文献速递睡眠呼吸障碍

CPAP治疗终止与全因死亡的关系:法国全国数据库分析

Relationship Between CPAP Termination and All-Cause Mortality: A French Nationwide Database Analysis.
PubMed 文献 · Chest · 2022-02-15

基于法国全国健康保险报销数据库,纳入18岁以上新使用CPAP的OSA患者,将首年内终止CPAP治疗者与继续使用者进行倾向评分匹配,每组88007例。继续CPAP治疗与较低的全因死亡风险相关(HR 0.61,95%CI 0.57-0.65,P<.01),新发心力衰竭也更少(HR 0.77,95%CI 0.71-0.82,P<.01)。

要点

  • 继续CPAP治疗与OSA患者全因死亡风险显著降低相关(HR 0.61)。
  • 继续CPAP治疗者新发心力衰竭风险也较低(HR 0.77)。
  • 真实世界数据支持持续使用CPAP以降低OSA患者死亡风险。

核心结论

  • 在OSA患者中,继续使用CPAP治疗与较低的全因死亡风险和新发心力衰竭风险相关。

研究设计与样本

  • 基于法国国家健康保险报销系统(SNDS)数据库,分析所有18岁以上新使用CPAP的患者。
  • 首年内终止CPAP治疗者与继续使用者进行倾向评分匹配,每组各88007例,平均年龄60岁,64%为男性。

主要发现

  • 继续CPAP治疗与终止相比,全因死亡风险显著降低(HR 0.61;95%CI 0.57-0.65;P<.01)。
  • 继续CPAP治疗者新发心力衰竭也更少(HR 0.77;95%CI 0.71-0.82;P<.01)。

临床怎么用

  • 真实世界数据提示应鼓励OSA患者持续使用CPAP治疗以降低全因死亡风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Randomized controlled trials have failed to demonstrate an effect of CPAP therapy on mortality. However, these studies have a number of important limitations, including low CPAP adherence, patient selection, and a small number of mortality events. RESEARCH QUESTION: What are the effects of CPAP therapy termination in the first year on all-cause mortality in patients with OSA from the Nationwide Claims Data Lake for Sleep Apnea study? STUDY DESIGN AND METHODS: Data from the Système National des Données de Santé (SNDS) database, the French national health insurance reimbursement system, for all new CPAP users ≥ 18 years of age were analyzed. The SNDS contains comprehensive, individualized, and anonymized data on health spending reimbursements for > 99% of all individuals living in France. OSA diagnosis was based on specific disease codes, whereas CPAP prescription was identified using specific treatment method codes. CPAP therapy termination was defined as the cessation of CPAP reimbursements triggered by the respiratory physician or sleep specialist in charge of follow-up. Patients who terminated therapy in the first year were propensity score matched with those who continued to use CPAP. The primary outcome was all-cause mortality. Three-year survival was visualized using Kaplan-Meier curves. Contributors to mortality also were determined. RESULTS: Data from two matched groups each including 88,007 patients were included (mean age, 60 years; 64% men). Continuation of CPAP therapy was associated with a significantly lower risk of all-cause death compared with CPAP therapy termination (hazard ratio [HR], 0.61; 95% CI, 0.57-0.65; P < .01, log-rank test). Incident heart failure also was less common in patients who continued vs terminated CPAP therapy (HR, 0.77; 95% CI, 0.71-0.82; P < .01). INTERPRETATION: These real-world data from a comprehensive, unbiased database highlight the potential for ongoing use of CPAP treatment to reduce all-cause mortality in patients with OSA.

来源:Chest,查看原文。版权归原作者所有。

引用

  1. Pépin JL, Bailly S, Rinder P, et al. Relationship Between CPAP Termination and All-Cause Mortality: A French Nationwide Database Analysis. Chest. 2022. PMID: 35176275. doi:10.1016/j.chest.2022.02.013

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。